NASDAQ · AVBP
Healthcare · Biotechnology
$13.02
Down-$0.07 (-0.52%)
Updated Nov 4, 2026, 6:14 PM
SID Score
3.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · AVBP
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
AVBP closed at $13.02 after 21 trading sessions, down 13.72% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $13.47 | $13.96 | $13.01 | $13.02 | 1.23M |
| Nov 2, 2026 | $14.89 | $14.99 | $13.255 | $13.35 | 1.24M |
| Oct 30, 2026 | $15.78 | $16.165 | $14.325 | $14.87 | 1.19M |
| Oct 29, 2026 | $15.87 | $16.42 | $15.73 | $15.95 | 658.31K |
| Oct 28, 2026 | $15.67 | $15.885 | $15.20 | $15.73 | 990K |
| Oct 27, 2026 | $15.45 | $15.69 | $15.00 | $15.40 | 1.58M |
| Oct 26, 2026 | $18.14 | $18.16 | $14.78 | $15.36 | 5.95M |
| Oct 23, 2026 | $19.00 | $21.23 | $18.18 | $21.00 | 3.28M |
| Oct 22, 2026 | $18.93 | $19.68 | $18.78 | $19.20 | 843.7K |
| Oct 21, 2026 | $19.07 | $19.44 | $18.68 | $19.12 | 1.49M |
| Oct 20, 2026 | $17.94 | $18.98 | $17.57 | $18.85 | 817.84K |
| Oct 19, 2026 | $16.82 | $18.14 | $16.7309 | $17.94 | 1.01M |
| Oct 16, 2026 | $16.86 | $17.23 | $16.485 | $16.66 | 1.33M |
| Oct 15, 2026 | $16.40 | $16.91 | $15.97 | $16.79 | 815.7K |
| Oct 14, 2026 | $16.06 | $16.615 | $15.26 | $16.20 | 1.59M |
| Oct 13, 2026 | $16.28 | $16.72 | $15.95 | $16.09 | 1.97M |
| Oct 12, 2026 | $16.57 | $16.78 | $16.262 | $16.46 | 1.34M |
| Oct 9, 2026 | $16.59 | $17.76 | $16.49 | $16.73 | 1.73M |
| Oct 8, 2026 | $16.62 | $16.91 | $15.78 | $16.71 | 2.16M |
| Oct 7, 2026 | $15.245 | $17.345 | $14.9677 | $16.89 | 4.33M |
| Oct 6, 2026 | $12.09 | $15.79 | $11.36 | $15.09 | 19.75M |
The latest Smart Investors Daily articles mentioning AVBP.
Company
Market Activity
Research & News
AVBP research
Company profile and research snapshot.
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 27, 2026 | Guggenheim | Buy | — |
| Oct 20, 2026 | B. Riley Securities | Buy | — |
| Oct 16, 2026 | BTIG | Buy | — |
| Oct 8, 2026 | HC Wainwright & Co. | Buy | — |
| Oct 7, 2026 | Truist Securities | Buy | — |
Generated Nov 4, 2026, 3:07 PM
ArriVent BioPharma (AVBP) gained 0.75% today following announcements regarding milestone achievements and partnership updates at the 17th Annual WADC Conference. The company's presentation of its MUTTA™ and AQUALINK™ platforms appears to have generated modest investor interest, though the modest price movement suggests cautious market reception.
Bottom line: AVBP's modest gain reflects modest investor interest in ArriVent's conference announcements regarding its pipeline platforms. While milestone achievements and partnership updates provide some positive momentum, the limited price movement suggests the market is waiting for more substantive clinical or commercial developments to drive significant gains. Investors should monitor upcoming clinical data and partnership announcements as key catalysts.
Yahoo · Nov 2, 2026
HAYWARD, Calif., November 02, 2026--Aarvik Therapeutics (Aarvik), an innovative, ADC-focused biotechnology company dedicated to engineering precision medicines for cancer therapy, is pleased to announce important updates to its partnership efforts.
Benzinga · Oct 27, 2026
Guggenheim analyst Michael Schmidt maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and raises the price target from $18 to $30.
Yahoo · Oct 27, 2026
ArriVent BioPharma (NASDAQ:AVBP) presented Phase I data for ARR-217, its CDH17-targeting antibody-drug conjugate, or ADC, in heavily pretreated metastatic colorectal cancer patients during a virtual webinar following an ESMO late-breaking oral presentation. The company said the early-stage study sh
Yahoo · Oct 27, 2026
ArriVent BioPharma (AVBP) is back in focus after releasing initial Phase 1 data for its CDH17-targeted antibody drug conjugate ARR-217 at the 2026 ESMO Congress and advancing the asset into Phase 1b. For context, ArriVent BioPharma shares closed at US$15.36 on 25 October, with the 1-day share price return declining 26.86% and the 30-day share price return down 46.01%. The 1-year total shareholder return has fallen a more modest 21.19%, suggesting recent enthusiasm around ARR-217 and...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning AVBP.
